A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need
暂无分享,去创建一个
Cynthia J. Musante | Craig J. Thalhauser | Sergey Ermakov | Brian J. Schmidt | C. Musante | B. Schmidt | Sergey Ermakov
[1] Ravi Iyengar,et al. Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .
[2] Jacky L. Snoep,et al. BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems , 2005, Nucleic Acids Res..
[3] J Chard,et al. Drug and Disease Model Resources: A Consortium to Create Standards and Tools to Enhance Model-Based Drug Development , 2013, CPT: pharmacometrics & systems pharmacology.
[4] Tove Tuntland,et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research , 2014, Front. Pharmacol..
[5] Arijit Chakravarty,et al. Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape , 2014, The AAPS Journal.
[6] K Biliouris,et al. MatVPC: A User-Friendly MATLAB-Based Tool for the Simulation and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.
[7] Hiroaki Kitano,et al. Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. , 2003, Omics : a journal of integrative biology.
[8] Tarek A. Leil,et al. Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..
[9] Mary Goldman,et al. Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.
[10] Manish Gupta,et al. QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models , 2017, The AAPS Journal.
[11] K Gadkar,et al. A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.
[12] Wolfgang Weiss,et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..
[13] R J Allen,et al. Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models , 2015, bioRxiv.
[14] Albert Wang,et al. Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..
[15] Neil Benson,et al. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.
[16] Marc R. Gastonguay,et al. Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve , 2015 .
[17] Johan Gabrielsson,et al. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.
[18] Hiroaki Kitano,et al. The ERATO Systems Biology Workbench: Enabling Interaction and Exchange Between Software Tools for Computational Biology , 2001, Pacific Symposium on Biocomputing.
[19] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[20] MN Trame,et al. Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.
[21] S. Visser,et al. Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.
[22] David J. Klinke,et al. Integrating Epidemiological Data into a Mechanistic Model of Type 2 Diabetes: Validating the Prevalence of Virtual Patients , 2008, Annals of Biomedical Engineering.
[23] J Wojciechowski,et al. Interactive Pharmacometric Applications Using R and the Shiny Package , 2015, CPT: pharmacometrics & systems pharmacology.
[24] MC Peterson,et al. FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.
[25] Shiew-Mei Huang,et al. The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.
[26] K Gadkar,et al. The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non‐obese diabetic mouse , 2010, Clinical and experimental immunology.
[27] White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation , 2013, CPT: pharmacometrics & systems pharmacology.
[28] Nail M. Gizzatkulov,et al. DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results , 2010, BMC Systems Biology.
[29] Fan Wu,et al. Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape , 2018, CPT: pharmacometrics & systems pharmacology.
[30] Fergal P. Casey,et al. Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.
[31] H. S. Lee,et al. Nutrient intake and urinary incontinence in Korean women: A propensity score‐matched analysis from the Korea National Health and Nutrition Examination Survey data , 2017, International journal of urology : official journal of the Japanese Urological Association.
[32] Edward W. Lowe,et al. Computational Methods in Drug Discovery , 2014, Pharmacological Reviews.